|
|
Post by centralcoastinvestor on Sept 4, 2018 13:39:14 GMT -5
As I have mentioned from time to time in other posts, I have been invested in MannKind since 2007. It has been absolutely brutal to be a shareholder most of that time. The ever present unrelenting shorting was so demoralizing. Today, I think we may have really turned the corner after so many false starts. I’m just enjoying the hell out of it and so should all of the other crazy longs that have stuck with this stock through thick and thin. Congratulations Mike Castagna and the whole MannKind team! WooooHoooo!
|
|
|
|
Post by ilovekauai on Sept 4, 2018 13:43:17 GMT -5
Thta's right CCI, it's been a long and winding road, but the path to profitability is now in sight. I've often said this is a war. Today was the shorts Waterloo moment, and they aren't on the wining side. It's going to be a great ride so fasten your seatbelts!
|
|
|
|
Post by akemp3000 on Sept 4, 2018 13:47:33 GMT -5
Yep. A couple of more good announcements and the long awaited squeeze might actually happen. Not predicting it but sure would love to see it.
|
|
|
|
Post by sugarland on Sept 4, 2018 13:55:17 GMT -5
A few consecutive weeks of rx totals over 1,000, and you’ll see it begin to happen. ! It’s coming !!
|
|
|
|
Post by awesomo on Sept 4, 2018 13:57:31 GMT -5
As far as I'm concerned, today was the best news we've had since Afrezza FDA approval.
|
|
|
|
Post by centralcoastinvestor on Sept 4, 2018 14:15:00 GMT -5
Broke $2 per share. Day is getter more fun.  |
|
|
|
Post by kc on Sept 4, 2018 14:19:23 GMT -5
Broke $2 per share. Day is getter more fun. CC I have to agree with you. The last four or five months I have been laying low because it’s upsetting to see the share price. Perhaps we will gain some momentum. This is a good deal for United therapeutics as their current device is so big and bulky that using a Technosphere type device opens a new market for them at a reduced cost of producing drug. Wider access to people who need this type of medication will be big for both companies. There are a lot of people with untreated COPD. |
|
|
|
Post by pguererro on Sept 4, 2018 14:25:20 GMT -5
Completely agree. Although we need this number to keep going up let’s take a moment to enjoy what is a big day for Mannkind and the patients that will benefit from Al Mann’s vision and genius!!!
|
|
|
|
Post by mnholdem on Sept 4, 2018 14:29:16 GMT -5
United Therapeutics’ CEO doesn’t seem to be the kind of person who would stab MannKind in the back. As you mentioned, her company has a COPD candidate in clinical testing. It seems that she could take full advantage of “Your Drug. Our Delivery.” - see MannKind Corporate website Partnering page.
|
|
|
|
Post by LongMNKD on Sept 4, 2018 14:29:59 GMT -5
Don't celebrate yet! okay.. shit, i guess you have to celebrate today haha. But I'm worried about the call after the close today. MNKD does not have a reputation for helping PPS in their calls.
|
|
|
|
Post by peppy on Sept 4, 2018 14:30:55 GMT -5
United Therapeutics’ CEO doesn’t seem to be the kind of person who would stab MannKind in the back. As you mentioned, her company has a COPD candidate in clinical testing. It seems that she could take full advantage of “Your Drug. Our Delivery.” - see MannKind Corporate website Partnering page. now we are talking. surfactant. www.accessdata.fda.gov/drugsatfda_docs/label/2008/020744s019lbl.pdfCUROSURF(ß (poractant alfa) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1 % hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C). It is suspended in 0.9% sodium chloride solution. The pH is adjusted as required with sodium bicarbonate to a pH of 6.2 (5.5 - 6.5). there would be a ton of money in surfactant |
|
|
|
Post by scottmnkd on Sept 4, 2018 14:34:31 GMT -5
As I have mentioned from time to time in other posts, I have been invested in MannKind since 2007. It has been absolutely brutal to be a shareholder most of that time. The ever present unrelenting shorting was so demoralizing. Today, I think we may have really turned the corner after so many false starts. I’m just enjoying the hell out of it and so should all of the other crazy longs that have stuck with this stock through thick and thin. Congratulations Mike Castagna and the whole MannKind team! WooooHoooo! To me, the most important development from today's press release means that Mannkind is no longer a one dimensional - Afrezza - company. Feeling much better about the crazy and brutal ride.  |
|
|
|
Post by lojothehus on Sept 4, 2018 14:50:37 GMT -5
Good job MNKD! Keep up the good. - Continue to stay focused on improving the lives of millions around the world suffering from diabetes.
- Continue to bring Al Mann's vision to all.
- Continue to pay the Shorts and the doubters back by decreasing their accounts.
- Continue to grow this company!
|
|
|
|
Post by beardawg on Sept 4, 2018 15:18:37 GMT -5
Broke $2 per share. Day is getter more fun. CC I have to agree with you. The last four or five months I have been laying low because it’s upsetting to see the share price. Perhaps we will gain some momentum. This is a good deal for United therapeutics as their current device is so big and bulky that using a Technosphere type device opens a new market for them at a reduced cost of producing drug. Wider access to people who need this type of medication will be big for both companies. There are a lot of people with untreated COPD. The best part about it is that United Therapeutics can just swap Mannkind's drug for theirs when they start selling it. They already have the customer base and I'm sure 100% of the current patients would switch to the new device. You have guaranteed customers from the beginning (without competing for them), instead of trying to drum up all new business. Then you add on the new patients that didn't take it because of the bulkiness. For UTHR it's a no brainer: cheaper production of device, more patients. |
|
|
|
Post by pantaloons on Sept 4, 2018 15:29:01 GMT -5
CC I have to agree with you. The last four or five months I have been laying low because it’s upsetting to see the share price. Perhaps we will gain some momentum. This is a good deal for United therapeutics as their current device is so big and bulky that using a Technosphere type device opens a new market for them at a reduced cost of producing drug. Wider access to people who need this type of medication will be big for both companies. There are a lot of people with untreated COPD. The best part about it is that United Therapeutics can just swap Mannkind's drug for theirs when they start selling it. They already have the customer base and I'm sure 100% of the current patients would switch to the new device. You have guaranteed customers from the beginning (without competing for them), instead of trying to drum up all new business. Then you add on the new patients that didn't take it because of the bulkiness. For UTC it's a no brainer: cheaper production of device, more patients. It would also not surprise me if insurance companies cover the TI-TrepT formulation much more readily, compared to Afrezza, since the route of administration is unchanged and costs may be much more comparable. |
|
